Trials / Not Yet Recruiting
Not Yet RecruitingNCT07467629
QLS5212 for Participants With Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS5212 Monotherapy in Participants With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS5212 | An anti-trophoblast glycoprotein antibody-drug conjugate |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2027-11-05
- Completion
- 2028-04-05
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07467629. Inclusion in this directory is not an endorsement.